Shots: The P-III POLARIX trial evaluates the efficacy, safety, and PK of Polivy + R-CHP vs R-CHOP in 879 patients in a ratio (1:1) with previously untreated DLBCL for 6 […]readmore
Tags : DLBCL
Shots: The approval is based on the P-II JULIET (NCT02445248) trial results assessing Kymriah (tisagenlecleucel) in patients with 1L+ DLBCL and followed by NICE approval in for pediatric and aged […]readmore
Shots: Post FDA approval in 2017, Yescarta (axicabtagene ciloleucel) receives EU marketing approval for the treatment of Relapsed or Refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell […]readmore